{"filing":{"accession_number":"0001213900-26-064796","cik":"0001946563","ticker":"SXTPW","company_name":"60 DEGREES PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-06-03","report_date":null,"primary_document":"ea0293532-8k_60degrees.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390026064796/ea0293532-8k_60degrees.htm"},"events":[{"id":7209,"run_id":6323,"accession_number":"0001213900-26-064796","anchor_item_number":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"summary":"The filing discloses the Company's intention to pursue a Commissioner's National Priority Review Voucher contingent on positive interim/final analysis results from its tafenoquine trial in severe babesiosis patients, with potential NDA submission targeted before Q1 2028. This represents a material regulatory development plan for a clinical-stage pharmaceutical company, but does not fit neatly into the standard taxonomy categories (not an earnings release, executive change, M\u0026A, impairment, or other defined event types). The disclosure is material to investors assessing the company's development pipeline and regulatory strategy, warranting classification as other_material.","company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTPW","filing_date":"2026-06-03","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":4031,"accession_number":"0001213900-26-064796","item_number":null,"item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The filing discloses the Company's intention to pursue a Commissioner's National Priority Review Voucher contingent on positive interim/final analysis results from its tafenoquine trial in severe babesiosis patients, with potential NDA submission targeted before Q1 2028. This represents a material regulatory development plan for a clinical-stage pharmaceutical company, but does not fit neatly into the standard taxonomy categories (not an earnings release, executive change, M\u0026A, impairment, or other defined event types). The disclosure is material to investors assessing the company's development pipeline and regulatory strategy, warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:43:41.404028+00:00","company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTPW","filing_date":"2026-06-03"}]}